PYXS Pyxis Oncology Inc.

FDA Catalyst Company
2.12
+0.1  (+5%)
Previous Close 2.02
Open 2.1
52 Week Low 1.96
52 Week High 19
Market Cap $69,561,353
Shares 32,811,959
Float 32,459,636
Enterprise Value $-208,289,843
Volume 103,411
Av. Daily Volume 172,364
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/02/2021
Jefferies Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/02/2021
Credit Suisse Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/02/2021

Latest News

  1. CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Company ended the quarter with approximately $247 million in cash and cash equivalents.

    Pyxis Oncology remains on target to file INDs for anti-EDB, PYX-201, and anti-Siglec-15, PYX-106, in the second half of 2022 and INDs for anti-CD123, PYX-203, and anti-KLRG1, PYX-102, in the second half of 2023. Further, as previously disclosed, the Company expects to provide an update on its anti-DLK1 ADC, PYX-202, in mid-2022.

    Financial Update

    • As of May 13, 2022, Pyxis…
    View Full Article
  2. CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:40 p.m. PT in Las Vegas, Nevada.

    A webcast of the fireside chat can be accessed on the Investors section of the Pyxis Oncology website at ir.pyxisoncology.com. Following the live event, a replay of the webcast will be archived for up to 90 days.

    About Pyxis Oncology, Inc.
    Pyxis Oncology, Inc. is a multi-asset multi-modality company…

    View Full Article
  3. - Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer -

    - Jan Pinkas, Ph.D., promoted to Chief Scientific Officer -

    - Company continues to advance programs toward the clinic with IND filings for
    Anti-EDB, PYX-201, and Anti-Siglec-15, PYX-106, expected in 2H22 -

    CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS) today announced the departure of Ronald Herbst, Ph.D., as the Company's Chief Scientific Officer and the appointment of Jan Pinkas, Ph.D., currently Senior Vice President, Preclinical Research & Development, to the position of Chief Scientific Officer. The management changes are effective as of April 12, 2022.

    "Ronald's passion, expertise and exceptional scientific leadership have…

    View Full Article
  4. - Data highlight PYX-106's differentiated activity profile and antitumor activity in an in vivo mouse model -

    - Preclinical data support IND filing in 2H 2022 -

    CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS) today announced preclinical data supporting the potential of anti-Siglec-15 BSI-060T (now PYX-106) presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, Louisiana, April 8-13, 2022.

    "While immunotherapies hold immense potential to improve the lives of patients with cancer, current therapeutics have demonstrated success in only a narrow range of tumor types," said Ronald Herbst, Ph.D…

    View Full Article
  5. - Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody

    - Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned upon advancement of PYX-106

    NEWARK, Del. and NANJING, China, March 29, 2022 /PRNewswire/ -- Biosion, Inc., a global R&D stage biotechnology company, today announced that Biosion and Pyxis Oncology (NASDAQ:PYXS) have entered into an agreement under which Pyxis Oncology will be granted an exclusive license to develop and commercialize Biosion's anti-Siglec-15 monoclonal antibody, BSI-060T (now referred to as PYX-106), world-wide, excluding Greater China

    View Full Article
View All Pyxis Oncology Inc. News